

5

Sheet 1 of 13

Form 1449\*

Atty. Docket No.: 295.027US1

Serial No. 09/150,813

INFORMATION DISCLOSURE STATEMENT  
BY APPLICANT  
(Use several sheets if necessary)

Applicants: David J. Grainger et al.

Filing Date: September 11, 1998

Group: 1646

U.S. PATENT DOCUMENTS

**Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
<i>h</i>	4,724,232	02/09/1988	Rideout et al.	514	50	09/17/85
<i>h</i>	4,737,580	04/12/1988	Twardzik et al.	530	388	09/26/86
<i>h</i>	5,079,228	01/07/1992	Cohen et al.	514	12	02/05/90
<i>h</i>	5,155,038	10/13/1992	Eyal et al.	435	240.2	02/22/90
<i>h</i>	5,202,118	04/13/1993	Gillis et al.	424	85.2	05/06/91
<i>h</i>	5,212,073	05/18/1993	Rollins et al.	435	69.5	05/12/89
<i>h</i>	5,248,666	09/28/1993	Twardzik et al.	514	12	04/29/92
<i>h</i>	5,302,384	04/12/1994	Gimbrone, Jr. et al.	424	85.2	02/25/93
<i>h</i>	5,357,041	10/18/1994	Roberts et al.	530	326	12/06/91
<i>h</i>	5,401,651	03/28/1995	Walz	435	240.2	10/16/91
<i>h</i>	5,491,130	02/13/1996	Roberts et al.	514	13	11/10/92
<i>h</i>	5,458,874	10/17/1995	Pereira et al.	424	85.1	10/30/92
<i>h</i>	5,459,128	10/17/1995	Rollins et al.	514	8	10/27/94
<i>h</i>	5,474,983	12/12/1995	Kuna et al.	514	12	03/15/93
<i>h</i>	5,556,757	09/17/1996	Alstyne et al.	435	7.2	06/07/95
<i>h</i>	5,571,713	11/05/1996	Lyle et al.	435	240.2	05/27/94
<i>h</i>	5,578,714	11/26/1996	Pogo et al.	536	23.5	10/21/93
<i>h</i>	5,605,671	02/25/1997	Lyle et al.	424	1.41	04/29/94
<i>h</i>	5,627,156	05/06/1997	Talmadge	514	13	09/23/94
<i>h</i>	5,646,117	07/08/1997	Matsushima et al.	514	12	03/25/95
<i>h</i>	5,650,150	07/22/1997	Gillies	424	134.1	07/27/94
<i>h</i>	5,661,132	08/26/1997	Eriksson et al.	514	44	11/22/94
<i>h</i>	5,705,360	01/06/1998	Rollins et al.	435	69.1	07/16/96
<i>h</i>	5,707,814	01/13/1998	Levy et al.	435	7.1	03/05/96
<i>h</i>	5,707,815	01/13/1998	Charo et al.	435	7.2	05/25/95
<i>h</i>	5,811,449	09/22/1998	Medford et al.	514	423	06/07/95
<i>h</i>	5,817,911	10/06/1998	Williams et al.	800	2	04/07/95
<i>h</i>	5,824,551	10/20/1998	Damme et al.	435	375	10/10/95
<i>h</i>	5,871,740	02/16/1999	Smith	424	186.1	09/26/96
<i>h</i>	5,877,276	03/02/1999	Talmadge	530	324	09/23/94

FOREIGN PATENT DOCUMENTS

**Examiner Initial	Document Number	Date	Country	Class	Subclass	Translation	
						Yes	No
<i>h</i>	0 281 363 B1	09/07/1988	European	C12N	15/18		
<i>h</i>	7-67689	03/14/1995	Japan				
<i>h</i>	9-255570 A	03/21/1996	Japan	A61K	031/35		
<i>h</i>	2 319 252 A	05/20/1998	Great Britain	C07K	14/16		


Examiner

Date Considered

2-17-00

\*Substitute Disclosure Statement Form (PTO-1449)

\*\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Form 1449\*

Atty. Docket No.: 295.027US1

Serial No. 09/150,813

INFORMATION DISCLOSURE STATEMENT  
BY APPLICANT

Applicants: David J. Grainger et al.

(Use several sheets if necessary)

Filing Date: September 11, 1998

Group: 1646

## FOREIGN PATENT DOCUMENTS

**Examiner Initial	Document Number	Date	Country	Class	Subclass	Translation	
						Yes	No
	0905241	03/31/1999	European	C12N	15/19		
	86/04334	07/31/1986	PCT	C07K	5/00		
	90/07863	07/26/1990	PCT	C07K	7/10		
	91/08483	06/13/1991	PCT	G01N	33/53		
	92/04372	03/19/1992	PCT	C07K	7/00		
	92/20372	11/26/1992	PCT	A61K	37/66		
	93/11159	06/10/1993	PCT	C07K	13/00		
	94/20512	09/15/1994	PCT	C07H	11/00		
	95/05191	02/23/1995	PCT	A61K	38/00		
	96/22371	07/25/1996	PCT	C12N	15/12		
	97/12615	04/10/1997	PCT	A61K	31/425		
	97/21812	06/19/1997	PCT	C12N	15/19		
	97/22698	06/26/1997	PCT	C12N	15/12		
	97/24325	07/10/1997	PCT	C07D	211/52		
	97/25427	07/17/1997	PCT	C12N	15/19		
	97/29192	08/14/1997	PCT	C12N	15/19		
	97/31098	08/28/1997	PCT	C12N	1/20		
	97/32019	09/04/1997	PCT	C12N	15/12		
	97/32993	09/12/1997	PCT	C12P	21/02		
	97/35010	09/25/1997	PCT	C12N	15/19		
	97/35982	10/02/1997	PCT	C12N	15/19		
	97/44462	11/27/1997	PCT	C12N	15/19		
	97/45543	12/04/1997	PCT	C12N	15/12		
	98/00535	12/08/1998	PCT	C12N	15/09		
	98/06703	02/19/1998	PCT	C07D	235/18		
	98/09171	03/05/1998	PCT	G01N	33/68		
	98/12324	03/26/1998	PCT	C12N	15/12		
	98/13495	04/02/1998	PCT	C12N	15/19		
	98/23750	06/04/1998	PCT	C12N	15/19		

## OTHER DOCUMENTS

(Including Author, Title, Date, Pertinent Pages, Etc.)

**Examiner Initial	
	"Blocking CCR5 Stops M-tropic HIV Infection", <u>Biotechnology News</u> , 17, 3 (1997).
	Adkins et al., "Zafirlukast -- A Review of its Pharmacology and Therapeutic Potential in the Management of Asthma", <u>Drugs</u> , 55, 121-144 (1998).


Examiner

Date Considered

2-17-00

\*Substitute Disclosure Statement Form (PTO-1449)

\*\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Sheet 3 of 13

Form 1449\*

Atty. Docket No.: 295.027US1

Serial No. 09/150,813

INFORMATION DISCLOSURE STATEMENT  
BY APPLICANT

(Use several sheets if necessary)

Applicants: David J. Grainger et al.

Filing Date: September 11, 1998

Group: 1646

## OTHER DOCUMENTS

(Including Author, Title, Date, Pertinent Pages, Etc.)

\*\*Examiner  
Initial

<i>h</i>	Albanesi et al., "Cetirizine and Hydrocortisone Differentially Regulate ICAM-1 Expression and Chemokine Release in Cultured Human Keratinocytes", <u>Clinical and Experimental Allergy</u> , 28, 101-109 (1998).
<i>h</i>	Alkhatib et al., "HIV-1 Coreceptor Activity of CCR5 and Its Inhibition by Chemokines: Independence from G Protein Signaling and Importance of Coreceptor Downmodulation", <u>Virology</u> , 234, 340-348 (1997).
<i>h</i>	Arenzana-Seisdedos et al., "HIV Blocked by Chemokine Antagonists", <u>Nature</u> , 383, 400 (1996).
<i>h</i>	Auer et al., "Crystallization and Preliminary X-ray Crystallographic Study of Interleukin-8", <u>FEBS Letters</u> , 265, 30-32 (1990).
<i>h</i>	Bacon et al., "Activation of Dual T Cell Signaling Pathways by the Chemokine RANTES", <u>Science</u> , 269, 1727-1730 (1995).
<i>h</i>	Bacon et al., "Chemokines in Disease Models and Pathogenesis", <u>Cytokine and Growth Factor Reviews</u> , 2, 167-173 (1998).
<i>h</i>	Baldwin et al., "Crystal Structure of Interleukin 8: Symbiosis of NMR and Crystallography", <u>Proc. Natl. Acad. Sci. USA</u> , 88, 502-506 (1991).
<i>h</i>	Baldwin et al., "Crystallization of Human Interleukin-8", <u>The Journal of Biological Chemistry</u> , 265, 6851-6853 (1990).
<i>h</i>	Beck-Schimmer et al., "Hyaluronan Induces Monocyte Chemoattractant Protein-1 Expression in Renal Tubular Epithelial Cells", <u>Journal of the American Society of Nephrology</u> , 9, 2283-2290 (1998).
<i>h</i>	Bernstein et al., "A Randomized Phase II Study of BB-10010: a Variant of Human Macrophage Inflammatory Protein-1alpha for Patients Receiving High-Dose Etoposide and Cyclophosphamide for Malignant Lymphoma and Breast Cancer", <u>British Journal of Haematology</u> , 99, 888-895 (1997).
<i>h</i>	Bodaghi et al., "Chemokine Sequestration by Viral Chemoreceptors as a Novel Viral Escape Strategy: Withdrawal of Chemokines from the Environment of Cytomegalovirus-infected Cells", <u>J. Exp. Med.</u> , 188, 855-866 (1998).
<i>a</i>	Boring et al., "Decreased Lesion Formation in CCR2-/- Mice Reveals a Role for Chemokines in the Initiation of Atherosclerosis", <u>Nature</u> , 394, 894-897 (1998).


Examiner

Date Considered

2-17-00

\*Substitute Disclosure Statement Form (PTO-1449)

\*\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Form 1449\*

Atty. Docket No.: 295.027US1

Serial No. 09/150,813

INFORMATION DISCLOSURE STATEMENT  
BY APPLICANT  
(Use several sheets if necessary)

Applicants: David J. Grainger et al.

Filing Date: September 11, 1998

Group: 1646

## OTHER DOCUMENTS

(Including Author, Title, Date, Pertinent Pages, Etc.)

\*\*Examiner  
Initial

<i>J</i>	Buckley, "Treatment of Rheumatoid Arthritis", <u>BMJ</u> , 315, 236-238 (1997).
<i>J</i>	Cairns, J.S., et al., "Chemokines and HIV-1 Second Receptors: The Therapeutic Connection", <u>Nature Medicine</u> , 4, 563-568, (May 1998)
<i>J</i>	Carron et al., "A Peptidomimetic Antagonist of the Integrin alpha(sub v)beta(sub 3) Inhibits Leydig Cell Tumor Growth and the Development of Hypercalcemia of Malignancy", <u>Cancer Research</u> , 58, 1930-1935 (1998).
<i>J</i>	Chakravarty et al., "Lysine 58 and Histidine 66 at the C-terminal alpha-Helix of Monocyte Chemoattractant Protein-1 are Essential for Glycosaminoglycan Binding", <u>The Journal of Biological Chemistry</u> , 273, 29641-29647 (1988).
<i>J</i>	Chung et al., "The Three-Dimensional Solution Structure of RANTES", <u>Biochemistry</u> , 34, 9307-9314 (1995).
<i>J</i>	Clark-Lewis et al., "Structure-Activity Relationships of Interleukin-8 Determined Using Chemical Synthesized Analogs", <u>The Journal of Biological Chemistry</u> , 266, 23128-23134 (1991).
<i>J</i>	Clark-Lewis et al., "Platelet Factor 4 Binds to Interleukin 8 Receptors and Activates Neutrophils When its N Terminus is Modified with Glu-Leu-Arg", <u>Proceedings of the National Academy of Sciences, USA</u> , 90, 3574-3577 (1993).
<i>J</i>	Clark-Lewis et al., "Structural Requirements for Interleukin-8 Function Identified by Design of Analogs and CXC Chemokine Hybrids", <u>J. Biol. Chem.</u> , 269, 16075-16081 (1994).
<i>J</i>	Clore et al., "Comparison of the Solution Nuclear Magnetic Resonance and Crystal Structures of Interleukin-8", <u>J. Mol. Biol.</u> , 217, 611-620 (1991).
<i>J</i>	Cocchi et al., "Identification of RANTES, MIP-1 $\alpha$ , and MIP-1 $\beta$ as the Major HIV-Suppressive Factors Produced by CD8+ T Cells", <u>Science</u> , 270, 1811-1815 (1995).
<i>J</i>	Cocchi et al., "The V3 Domain of the HIV-1 gp120 Envelope Glycoprotein is Critical for Chemokine-Mediated Blockade of Infection", <u>Nature Medicine</u> , 11, 1244-1247 (1996).
<i>J</i>	DeBie et al., "Modulation of Airway Hyperresponsiveness and Eosinophilia by Selective Histamine and 5-HT Receptor Antagonists in a Mouse Model of Allergic Asthma", <u>British Journal of Pharmacology</u> , 124, 857-864 (1998).

Examiner

Date Considered

2-17-00

\*Substitute Disclosure Statement Form (PTO-1449)

\*\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Form 1449\*

Atty. Docket No.: 295.027US1

Serial No. 09/150,813

INFORMATION DISCLOSURE STATEMENT  
BY APPLICANT

Applicants: David J. Grainger et al.

(Use several sheets if necessary)

Filing Date: September 11, 1998

Group: 1646

## OTHER DOCUMENTS

\*\*Examiner  
Initial

(Including Author, Title, Date, Pertinent Pages, Etc.)

f	Doranz et al., "A Small-molecule Inhibitor Directed Against the Chemokine Receptor CXCR4 Prevents its Use as an HIV-1 Coreceptor", <u>J. Exp. Med.</u> , 186, 1395-1400 (1997).
f	Drazen et al., "Treatment of Chronic Stable Asthma with Drugs Active on the 5-Lipoxygenase Pathway", <u>Int. Arch. Allergy Immunol.</u> , 107, 319-320 (1995).
f	Fairbrother et al., "The Solution Structure of Melanoma Growth Stimulating Activity", <u>Journal of Molecular Biology</u> , 242, 252-270 (1994).
f x	Gong et al., "Antagonists of Monocyte Chemoattractant Protein 1 Identified by Modification of Functionally Critical NH2-terminal Residues", <u>J. Exp. Med.</u> , 181, 631-640 (1995).
f x	Gong et al., "An Antagonist of Monocyte Chemoattractant Protein 1 (MCP-1) Inhibits Arthritis in the MRL-lpr Mouse Model", <u>J. Exp. Med.</u> , 186, 131-137 (1997).
f	Gosling et al., "Molecular Uncoupling of C-C Chemokine Receptor 5-Induced Chemotaxis and Signal Transduction from HIV-1 Coreceptor Activity", <u>Proc. Natl. Acad. Sci. USA</u> , 94, 5061-5066 (1997).
f	Grossman et al., "Results of the First U.S. Double-Blind, Placebo-Controlled, Multicenter Clinical Study in Asthma with Pranlukast, a Novel Leukotriene Receptor Antagonist", <u>Journal of Asthma</u> , 34, 321-328 (1997).
f	Hauser, "Therapeutic Strategies for Multiple Sclerosis", <u>J. Neurochem.</u> , 69 Suppl., Abstract A, S219 (1997).
f	Hendeles et al., "Zafirlukast for Chronic Asthma: Convenient and Generally Safe, But Is It Effective?", <u>The Annals of Pharmacology</u> , 31, 1084-1086 (1997).
f	Heveker et al., "Dissociation of the Signalling and Antiviral Properties of SDF-1-Derived Small Peptides", <u>Current Biology</u> , 8, 369-376 (1998).
f	Hilliquin et al., "Treatment of Rheumatoid Arthritis with Platelet Activating Factor Antagonist BN 50730", <u>J. Rheumatol.</u> , 22, 1651-1654 (1995).
f	Hogan et al., "Cytokines as Targets for the Inhibition of Eosinophilic Inflammation", <u>Pharmacol. Ther.</u> , 74, 259-283 (1997).

Examiner

Date Considered

\*Substitute Disclosure Statement Form (PTO-1449)

\*\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Form 1449\*

Atty. Docket No.: 295.027US1

Serial No. 09/150,813

INFORMATION DISCLOSURE STATEMENT  
BY APPLICANT  
(Use several sheets if necessary)

Applicants: David J. Grainger et al.

Filing Date: September 11, 1998

Group: 1646

## OTHER DOCUMENTS

(Including Author, Title, Date, Pertinent Pages, Etc.)

\*\*Examiner  
Initial


<i>h</i>	Howard et al., "Small Molecule Inhibitor of HIV-1 Cell Fusion Blocks Chemokine Receptor-mediated Function", <u>Journal of Leukocyte Biology</u> , <u>64</u> , 6-13 (1998).
<i>h</i>	Hunter et al., "BB-10010: An Active Variant of Human Macrophage Inflammatory Protein 1- $\alpha$ With Improved Pharmaceutical Properties", <u>Blood</u> , <u>96</u> , 4400-4408 (1995).
<i>h</i>	Ishikawa et al., "Effect of YM934, a Novel Potassium-Channel Opener, in Various Experimental Asthma Models in Guinea-pigs", <u>J. Pharm. Pharmacol.</u> , <u>48</u> , 1034-1040 (1996).
<i>h</i>	Israel et al., "Effect of Treatment With Zileuton, a 5-Lipoxygenase Inhibitor, in Patients With Asthma", <u>JAMA</u> , <u>275</u> , 931-936 (1996).
<i>h</i>	Jameson et al., "A Rationally Designed CD4 Analogue Inhibits Experimental Allergic Encephalomyelitis", <u>Nature</u> , <u>368</u> , 744-745 (1994).
<i>h</i>	Katz et al., "Octreotide, a New Somatostatin Analogue", <u>Clinical Pharmacy</u> , <u>8</u> , 255-273 (1989).
<i>h</i>	Kelloway, "Zafirlukast: The First Leukotriene-Receptor Antagonist Approved for the Treatment of Asthma", <u>The Annals of Pharmacology</u> , <u>31</u> , 1012-1021 (1997).
<i>h</i>	Klareskog et al., "Immunopathogenesis and Immunotherapy in Rheumatoid Arthritis: an Area in Transition", <u>Journal of Internal Medicine</u> , <u>238</u> , 191-206 (1995).
<i>h</i>	Kledel et al., "A Broad-Spectrum Chemokine Antagonist Encoded by Kaposi's Sarcoma-Associated Herpesvirus", <u>Science</u> , <u>277</u> , 1656-1659 (1997).
<i>h</i>	Kullberg et al., "Cytokines as Therapy for Opportunistic Fungal Infections", <u>Res. Immunol.</u> , <u>149</u> , 478-488 (1998).
<i>h</i>	Lecomte-Raclet et al., "New Insights into the Negative Regulation of Hematopoiesis by Chemokine Platelet Factor 4 and Related Peptides", <u>Blood</u> , <u>91</u> , 2772-2780 (1998).
<i>h</i>	Lee et al., "Influence of the CCR2-V64I Polymorphism on Human Immunodeficiency Virus Type 1 Coreceptor Activity and on Chemokine Receptor Function of CCR2b, CCR3, CCR5, and CXCR4", <u>Journal of Virology</u> , <u>72</u> , 7450-7458 (1998).

Examiner

Date Considered

\*Substitute Disclosure Statement Form (PTO-1449)

\*\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Form 1449\*

Atty. Docket No.: 295.027US1

Serial No. 09/150,813

INFORMATION DISCLOSURE STATEMENT  
BY APPLICANT

(Use several sheets if necessary)

Applicants: David J. Grainger et al.

Filing Date: September 11, 1998

Group: 1646

## OTHER DOCUMENTS

(Including Author, Title, Date, Pertinent Pages, Etc.)

\*\*Examiner  
Initial

h	Leong et al., "Complete Mutagenesis of the Extracellular Domain of Interleukin-8 (IL-8) Type A Receptor Identifies Charged Residues Mediating IL-8 Binding and Signal Transduction", <u>Journal of Biological Chemistry</u> , 19343-19348 (1994).
g	Lowe et al., "The Endothelium in Psoriasis", <u>British Journal of Dermatology</u> , 132, 497-505 (1995).
g	Lu et al., "Abnormalities in Monocyte Recruitment and Cytokine Expression in Monocyte Chemoattractant Protein 1-deficient Mice", <u>Journal of Experimental Medicine</u> , 187, 601-608 (1998).
g	Lukacs et al., "C-C Chemokines Differentially Alter Interleukin-4 Production from Lymphocytes", <u>American Journal of Pathology</u> , 150, 1861-1868 (1997).
g	Lukacs et al., "Airway Hyperreactivity is Associated with Specific Leukocyte Subset Infiltration in a Mouse Model of Allergic Airway Inflammation", <u>Pathobiology</u> , 64, 308-313 (1996).
g	Lusti-Narasimhan et al., "Molecular Switch of Chemokine Receptor Selectivity", <u>J. Biol. Chem.</u> , 271, 3148-3153 (1996).
g	Malkowski et al., "The Crystal Structure of Recombinant Human Neutrophil-Activating Peptide-2 (M6L) at 1.9-Angstrom Resolution", <u>The Journal of Biological Chemistry</u> , 270, 7077-7087 (1995).
g	Marone, "Asthma: Recent Advances", <u>Immunology Today</u> , 19, 5-9 (1998).
g	Maurer et al., "Chemokines and the Regulation of Hematopoiesis", <u>C.R. Seances Soc. Biol. Fil.</u> , 192, 917-923 (1998).
g	Mehlhop et al., "Allergen-induced Bronchial Hyperreactivity and Eosinophilic Inflammation Occur in the Absence of IgE in a Mouse Model of Asthma", <u>Proceedings of the National Academy of Sciences USA</u> , 94, 1344-1349 (1997).
g	Miller et al., "A Synthetic Peptide which Specifically Inhibits Heat-Treated Interleukin-8 Binding and Chemotaxis for Neutrophils", <u>Agents Actions</u> , 40, 200-208 (1993).
g	Molling, "Naked DNA for Vaccine or Therapy", <u>J. Mol. Med.</u> , 75, 242-246 (1997).



Examiner

Date Considered

2-17-06

\*Substitute Disclosure Statement Form (PTO-1449)

\*\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Form 1449\*

App. Docket No.: 295.027US1

Serial No. 09/150,813

INFORMATION DISCLOSURE STATEMENT  
BY APPLICANT  
(Use several sheets if necessary)

Applicants: David J. Grainger et al.

Filing Date: September 11, 1998

Group: 1646

## OTHER DOCUMENTS

(Including Author, Title, Date, Pertinent Pages, Etc.)

\*\*Examiner  
Initial

<i>J</i>	Montecclaro et al., "Role of the Amino Terminus in Ligand Binding and Signal Transduction of the Human Monocyte Chemoattractant Protein-1 Receptor", <u>Circulation Supplement I</u> , 92, 160 (1995).
<i>J</i>	Moser et al., "Interleukin-8 Antagonists Generated by N-Terminal Modification", <u>The Journal of Biological Chemistry</u> , 268, 7125-7128 (1993).
<i>J</i>	Murakami et al., "A Small Molecule CXCR4 Inhibitor that Blocks T Cell Line-tropic HIV-1 Infection", <u>J. Exp. Med.</u> , 186, 1389-1393 (1997).
<i>J</i>	Myers et al., "Collagen-Induced Arthritis, an Animal Model of Autoimmunity", <u>Life Sciences</u> , 61, 1861-1878 (1997).
<i>J</i>	Nagamatsu et al., "Hydrolysis of Lysine Peptides by Plasmin", <u>Chem. Pharm. Bull.</u> , 22, 2680-2684 (1974).
<i>J</i>	Noguchi et al., "Isolation and Identification of Acidic Oligopeptides Occurring in a Flavor Potentiating Fraction From a Fish Protein Hydrolysate", <u>J. Agric. Food. Chem.</u> , 23, 49-53 (1975).
<i>J</i>	O'Brien et al., "Anti-Human Immunodeficiency Virus Type 1 Activity of an Oligocationic Compound Mediated via gp120 V3 Interactions", <u>Journal of Virology</u> , 70, 2825-2831 (1996).
<i>J</i>	O'Brien et al., "Chemotaxis of Alveolar Macrophages in Response to Signals Derived from Alveolar Epithelial Cells", <u>J. Lab. Clin. Med.</u> , 131, 417-424 (1998).
<i>J</i>	O'Hehir et al., "Regulation of Cytokine and Chemokine Transcription in a Human TH2 Type T-cell Clone During the Induction Phase of Anergy", <u>Clinical and Experimental Allergy</u> , 26, 20-27 (1996).
<i>J</i>	Panettieri et al., "Effects of LTD4 on Human Airway Smooth Muscle Cell Proliferation, Matrix Expression, and Contraction In Vitro: Differential Sensitivity to Cysteinyl Leukotriene Receptor Antagonists", <u>Am J. Respir. Cell Mol. Biol.</u> , 18, 453-461 (1998).
<i>J</i>	Pease et al., "Microbial Corruption of the Chemokine System: An Expanding Paradigm", <u>Seminars in Immunology</u> , 10, 169-178 (1998).

Examiner

Date Considered

2-17-00

\*Substitute Disclosure Statement Form (PTO-1449)

\*\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Form 1449\*

Atty. Docket No.: 295.027US1

Serial No. 09/150,813

INFORMATION DISCLOSURE STATEMENT  
BY APPLICANT

(Use several sheets if necessary)

Applicants: David J. Grainger et al.

Filing Date: September 11, 1998

Group: 1646

## OTHER DOCUMENTS

(Including Author, Title, Date, Pertinent Pages, Etc.)

\*\*Examiner  
Initial

h	Pease et al., "The N-terminal Extracellular Segments of the Chemokine Receptors CCR1 and CCR3 Are Determinants for MIP-1 $\alpha$ and Eotaxin Binding, Respectively, but a Second Domain is Essential for Efficient Receptor Activation", <u>The Journal of Biological Chemistry</u> , 273, 19972-19976 (1998).
g	Plater-Zyberk et al., "Effect of a CC Chemokine Receptor Antagonist on Collagen Induced Arthritis in DBA/1 Mice", <u>Immunology Letters</u> , 57, 117-120 (1997).
g	Porshke et al., "The Conformation of Single Stranded Oligonucleotides and of Oligonucleotide-oligopeptide Complexes from their Rotation Relaxation in the Nanosecond Time Range", <u>J. Biomol. Struct. Dyn.</u> , 2, 1173-1184 (1985).
g	Postlethwaite et al., "Identification of a Chemotactic Epitope in Human Transforming Growth Factor- $\beta$ 1 Spanning Amino Acid Residues 368-374", <u>Journal of Cellular Physiology</u> , 164, 587-592 (1995).
g	Premack et al., "Chemokine Receptors: Gateways to Inflammation and Infection", <u>Nature Medicine</u> , 2, 1174-1178 (1996).
g	Proost et al., "Amino-terminal Truncation of Chemokines by CD26/Dipeptidyl-peptidase IV", <u>The Journal of Biological Chemistry</u> , 273, 7222-7227 (1998).
g	Reiss et al., "Effects of Montelukast (MK-0476), A New Potent Cysteinyl Leukotriene (LTD <sub>4</sub> ) Receptor Antagonist, in Patients with Chronic Asthma", <u>J. Allergy Clin. Immunol.</u> , 98, 528-534 (1996).
g	Sadek et al., "Chemokines Induced by Infection of Mononuclear Phagocytes with Mycobacteria and Present in Lung Aveoli During Active Pulmonary Tuberculosis", <u>American Journal of Respiratory Cell and Molecular Biology</u> , 19, 513-521 (1998).
g	Sanders et al., "Chemokines and Receptors in HIV Encephalitis", <u>AIDS</u> , 12, 1021-1026 (1998).
a	Sato et al., "A Simple and Rapid Method for Preliminary Evaluation of In Vivo Efficacy of Anti-HIV Compounds in Mice", <u>Antiviral Research</u> , 27, 151-163 (1995).


Examiner

Date Considered

2-7-00

\*Substitute Disclosure Statement Form (PTO-1449)

\*\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Form 1449\*

Atty. Docket No.: 295.027US1

Serial No. 09/150,813

INFORMATION DISCLOSURE STATEMENT  
BY APPLICANT  
(Use several sheets if necessary)

Applicants: David J. Grainger et al.

Filing Date: September 11, 1998

Group: 1646

## OTHER DOCUMENTS

(Including Author, Title, Date, Pertinent Pages, Etc.)

\*\*Examiner  
Initial

<i>h</i>	Schultz-Cherry, S., et al., "Regulation of Transforming Growth Factor-Beta Activation by Discrete Sequences of Thrombospondin 1", <u>The Journal of Biological Chemistry</u> , 270, 7304-7310, (Mar. 31, 1995)
<i>g</i>	Schultz-Cherry, S., et al., "The Type 1 Repeats of Thrombospondin 1 Activate Latent Transforming Growth Factor-Beta", <u>The Journal of Biological Chemistry</u> , 269, 26783-26788, (Oct. 28, 1994)
<i>h</i>	Schultz-Cherry, S., et al., "Thrombospondin Causes Activation of Latent Transforming Growth Factor-Beta Secreted by Endothelial Cells by a Novel Mechanism", <u>The Journal of Cell Biology</u> , 122, 923-932, (Aug. 1993)
<i>h</i>	Simmons et al., "Potent Inhibition of HIV-1 Infectivity in Macrophages and Lymphocytes by a Novel CCR5 Antagonist", <u>Science</u> , 276, 276-279 (1997).
<i>h</i>	Skelton et al., "Proton NMR Assignments and Solution Conformation of RANTES, a Chemokine of the C-C Type", <u>Biochemistry</u> , 34, 5329-5342 (1995).
<i>h</i>	Smith et al., "Inhibition of Leukotriene D4-Induced Bronchoconstriction in Subjects With Asthma: A Concentration-Effect Study of ICI 204,219", <u>Clin. Pharmacol. Ther.</u> , 54, 430-436 (1993).
<i>h</i>	Sneller et al., "An Analysis of Forty-Two Wegener's Granulomatosis Patients Treated with Methotrexate and Prednisone", <u>Arthritis and Rheumatism</u> , 38, 608-613 (1995).
<i>h</i>	Spector, "Leukotriene Activity Modulation in Asthma", <u>Drugs</u> , 54, 369-384 (1997).
<i>h</i>	Spector et al., "Effects of 6 Weeks of Therapy with Oral Doses of ICI 204,219, a Leukotriene D4 Receptor Antagonist, in Subjects with Bronchial Asthma", <u>Am. J. Respir. Crit. Care Med.</u> , 150, 618-623 (1994).
<i>h</i>	Steitz et al., "Mapping of MCP-1 Functional Domains by Peptide Analysis and Site-Directed Mutagenesis", <u>FEBS Letters</u> , 430, 158-164 (1998).
<i>g</i>	Suissa et al., "Effectiveness of the Leukotriene Receptor Antagonist Zafirlukast for Mild-to-Moderate Asthma", <u>Ann. Intern. Med.</u> , 126, 177-183 (1997).

Examiner

Date Considered

2-17-00

\*Substitute Disclosure Statement Form (PTO-1449)

\*\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Form 1449*	Atty. Docket No.: 295.027US1	Serial No. 09/150,813
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	Applicants: David J. Grainger et al.	
	Filing Date: September 11, 1998	Group: 1646

## OTHER DOCUMENTS

(Including Author, Title, Date, Pertinent Pages, Etc.)

\*\*Examiner  
Initial

<i>J</i>	Szabo et al., "Chemokine Class Differences in Binding to the Duffy Antigen-Erythrocyte Chemokine Receptor", <u>The Journal of Biological Chemistry</u> , 270, 25348-25351 (1995).
<i>J</i>	Tamura et al., "Effect of a Potent Platelet-Activating Factor Antagonist, WEB-2086, on Asthma", In: <u>Platelet-Activating Factor and Related Lipid Mediators</u> , 2, Nigam, et al., (eds.), Plenum Press, New York, 371-380 (1996).
<i>J</i>	Taylor et al., "The Mechanism of Action of Corticosteroids in Asthma", <u>Respiratory Medicine</u> , 87, 261-277 (1993).
<i>J</i>	Terkeltaub et al., "The Murine Homolog of the Interleukin-8 Receptor CXCR-2 is Essential for the Occurrence of Neutrophilic Inflammation in the Air Pouch Model of Acute Urate Crystal-induced Gouty Synovitis", <u>Arthritis and Rheumatism</u> , 41, 900-909 (1998).
<i>J</i>	Thompson et al., "Design and Evaluation of Small Peptides Mapping the Exposed Surface of IL-8", 47, 214-218 (1996).
<i>J</i>	Tian et al., "A Small, Nonpeptidyl Mimic of Granulocyte--Colony-Stimulating Factor", <u>Science</u> , 281, 257-259 (1998).
<i>J</i>	Valente et al., "Characterization of Monocyte Chemotactic Protein-1 Binding to Human Monocytes", <u>Biochemical and Biophysical Research Communications</u> , 176, 309-314 (1991).
<i>J</i>	Waltenberger, "Modulation of Growth Factor Action- Implications for the Treatment of Cardiovascular Diseases", <u>Circulation</u> , 96, 4083-4094 (1997).
<i>J</i>	Wang et al., "Induction of Interleukin-8 in Foam Cells Induced by Acetylated LDL", <u>Circulation Supplement</u> , 92, 160 (1995).
<i>J</i>	Wang et al., "Chemokines, Receptors and Their Role in Cardiovascular Pathology", <u>Int. J. Clin. Lab. Res.</u> , 28, 83-90 (1998).
<i>J</i>	Weber et al., "Deletion of the NH2-Terminal Residue Converts Monocyte Chemotactic Protein 1 from an Activator of Basophil Mediator Release to an Eosinophil Chemoattractant", <u>J. Exp. Med.</u> , 183, 681-685 (1996).


Examiner

Date Considered

2/20/00

\*Substitute Disclosure Statement Form (PTO-1449)

\*\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Form 1449*	Atty. Docket No.: 295.027US1	Serial No. 09/150,813
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	Applicants: David J. Grainger et al.	
	Filing Date: September 11, 1998	Group: 1646

## OTHER DOCUMENTS

(Including Author, Title, Date, Pertinent Pages, Etc.)

\*\*Examiner  
Initial

J	Wells et al., "The Molecular Basis of Selectivity Between CC and CXC Chemokines: The Possibility of Chemokine Antagonists as Anti-Inflammatory Agents", <u>Annals of New York Academy of Sciences</u> , 796, 245-257 (1996).
J	Wells et al., "The Molecular Basis of the Chemokine/Chemokine Receptor Interaction -- Scope for Design of Chemokine Antagonists", <u>Methods: A Companion to Methods in Enzymology</u> , 10, 126-134 (1996).
J	White et al., "Identification of a Potent, Selective Non-peptide CXCR2 Antagonist That Inhibits Interleukin-8-induced Neutrophil Migration", <u>The Journal of Biological Chemistry</u> , 273, 10095-10098 (1998).
J	Wooley et al., "Influence of a Recombinant Human Soluble Tumor Necrosis Factor Receptor FC Fusion Protein on Type II Collagen-Induced Arthritis in Mice", <u>The Journal of Immunology</u> , 151, 6602-6607 (1993).
J	Yahi et al., "SPC3, A Synthetic Peptide Derived from the V3 Domain of Human Immunodeficiency Virus Type 1 (HIV-1) Gp120, Inhibits HIV-1 Entry into CD4(plus) and CD4(minus) Cells by Two Distinct Mechanisms", <u>Proc. Natl. Acad. Sci. USA</u> , 92, 4867-4871 (1995).
J	Yang et al., "Phenotypic Knockout of HIV Type 1 Chemokine Coreceptor CCR-5 by Intrakines as Potential Therapeutic Approach for HIV-1 Infection", <u>Proc. Natl. Acad. Sci. USA</u> , 94, 11567-11572 (1997).
J	Yang et al., "Antigen-Induced Eosinophilic Lung Inflammation Develops in Mice Deficient in Chemokine Eotaxin", <u>Blood</u> , 92, 3912-3923 (1998).
J	Zagorski et al., "Inhibition of Acute Peritoneal Inflammation in Rats by a Cytokine-induced Neutrophil Chemoattractant Receptor Antagonist", <u>The Journal of Immunology</u> , 159, 1059-1062 (1997).
J	Zeyneloglu et al., "The Effect of Monocyte Chemotactic Protein 1 in Intraperitoneal Adhesion Formation in a Mouse Model", <u>Am. J. Obstet. Gynecol.</u> , 179, 438-443 (1998).
J	Zhang et al., "A Dominant Negative Inhibitor Indicates that Monocyte Chemoattractant Protein 1 Functions as a Dimer", <u>Mol. and Cell Biol.</u> , 15, 4851-4855 (1995).

Examiner 	Date Considered 2-17-00
--	-------------------------

\*Substitute Disclosure Statement Form (PTO-1449)

\*\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.





Form 1449*	Atty. Docket No.: 295.027US1	Serial No. 09/150,813
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	Applicants: David J. Grainger et al.	
	Filing Date: September 11, 1998	Group: 1646

## OTHER DOCUMENTS

(Including Author, Title, Date, Pertinent Pages, Etc.)

**\*\*Examiner**  
Initial

	Zhang et al., "Structure/Activity Analysis of Human Monocyte Chemoattractant Protein-1 (MCP-1) by Mutagenesis", <u>J. Biol. Chem.</u> , 269, 15918-15924 (1994).
	Zou et al., "Function of the Chemokine Receptor CXCR4 in Haematopoiesis and in Cerebellar Development", <u>Nature</u> , 393, 595-598 (1998).

Examiner

Date Considered

2-17-00

\*Substitute Disclosure Statement Form (PTO-1449)

**\*\*EXAMINER:** Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.